Compare AANJANEYA LIFECARE with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs AUROBINDO PHARMA - Comparison Results

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS AUROBINDO PHARMA DR. DATSONS LABS/
AUROBINDO PHARMA
 
P/E (TTM) x -10.9 14.0 - View Chart
P/BV x 0.2 3.0 5.3% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 DR. DATSONS LABS   AUROBINDO PHARMA
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
AUROBINDO PHARMA
Mar-18
DR. DATSONS LABS/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs126809 15.5%   
Low Rs31504 6.1%   
Sales per share (Unadj.) Rs133.0281.1 47.3%  
Earnings per share (Unadj.) Rs0.241.4 0.4%  
Cash flow per share (Unadj.) Rs6.650.9 13.0%  
Dividends per share (Unadj.) Rs02.50 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs128.8199.4 64.6%  
Shares outstanding (eoy) m31.66585.88 5.4%   
Bonus/Rights/Conversions FCCB--  
Price / Sales ratio x0.62.3 25.2%   
Avg P/E ratio x516.115.9 3,251.2%  
P/CF ratio (eoy) x11.812.9 91.8%  
Price / Book Value ratio x0.63.3 18.5%  
Dividend payout %06.0 0.0%   
Avg Mkt Cap Rs m2,477384,630 0.6%   
No. of employees `000NA17.3 0.0%   
Total wages/salary Rs m5621,308 0.3%   
Avg. sales/employee Rs ThNM9,500.7-  
Avg. wages/employee Rs ThNM1,229.4-  
Avg. net profit/employee Rs ThNM1,397.9-  
INCOME DATA
Net Sales Rs m4,211164,666 2.6%  
Other income Rs m791,020 7.7%   
Total revenues Rs m4,289165,686 2.6%   
Gross profit Rs m56937,718 1.5%  
Depreciation Rs m2045,580 3.7%   
Interest Rs m430777 55.4%   
Profit before tax Rs m1332,380 0.0%   
Minority Interest Rs m031 0.0%   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m68,183 0.1%   
Profit after tax Rs m524,229 0.0%  
Gross profit margin %13.522.9 59.0%  
Effective tax rate %48.025.3 190.1%   
Net profit margin %0.114.7 0.8%  
BALANCE SHEET DATA
Current assets Rs m6,852121,878 5.6%   
Current liabilities Rs m6,71186,806 7.7%   
Net working cap to sales %3.321.3 15.7%  
Current ratio x1.01.4 72.7%  
Inventory Days Days161130 123.9%  
Debtors Days Days31868 465.8%  
Net fixed assets Rs m3,67381,037 4.5%   
Share capital Rs m317586 54.0%   
"Free" reserves Rs m3,761116,218 3.2%   
Net worth Rs m4,078116,804 3.5%   
Long term debt Rs m1,6714,512 37.0%   
Total assets Rs m12,633211,052 6.0%  
Interest coverage x1.042.7 2.4%   
Debt to equity ratio x0.40 1,060.8%  
Sales to assets ratio x0.30.8 42.7%   
Return on assets %3.411.8 29.1%  
Return on equity %0.120.7 0.6%  
Return on capital %7.727.4 28.0%  
Exports to sales %22.90-   
Imports to sales %14.30-   
Exports (fob) Rs m964NA-   
Imports (cif) Rs m602NA-   
Fx inflow Rs m96480,727 1.2%   
Fx outflow Rs m60734,700 1.7%   
Net fx Rs m35746,027 0.8%   
CASH FLOW
From Operations Rs m1,34519,548 6.9%  
From Investments Rs m-2,256-19,570 11.5%  
From Financial Activity Rs m-1,2008,642 -13.9%  
Net Cashflow Rs m-2,1118,922 -23.7%  

Share Holding

Indian Promoters % 4.5 54.1 8.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 8.0 -  
FIIs % 1.4 27.7 4.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 94.1 10.2 922.5%  
Shareholders   20,807 69,601 29.9%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  ALEMBIC LTD  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare DR. DATSONS LABS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps 470 Points; Energy and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended deep in the red. The BSE Sensex fell over 550 points intraday and breached the 36,000 mark.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

MSTC IPO: Should You Bet on This State-Run E-Commerce Player? (IPO)

Mar 13, 2019

Should you subscribe to the IPO of MSPC Limited?

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS - LUPIN COMPARISON

COMPARE DR. DATSONS LABS WITH

MARKET STATS